Intas Pharmaceuticals Ltd - Company Profile
Powered by 
All the sales intelligence you need on Intas Pharmaceuticals Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Intas Pharmaceuticals Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Intas Pharmaceuticals Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Intas Pharmaceuticals Ltd (Intas) develops, manufactures, and commercializes pharmaceuticals and biotechnology products. The company offers products such as sevelamer, ciprofloxacin, amitriptyline, erythropoietin, filgrastim, follicle-stimulating hormone (FSH), rituximab, ampicillin, albendazole, benazepril, and carprofen, among others. It also develops recombinant DNA protein (rDNA) products and plasma-derived products for oncology, auto-immune, ophthalmology, nephrology, and plasma-derived product-based therapies. It has formulation manufacturing facilities and active pharmaceutical ingredients (API) and intermediate facilities in India. The company markets products through an internal sales force and a network of distributors worldwide. Intas is headquartered in Ahmedabad, Gujarat, India.
Headquarters
India
Address
Corporate House, S. G. Highway, Near Sola Bridge, Thaltej, Ahmedabad, Gujarat, 380054
Website
www.intaspharma.com
Telephone
91 79 61577000
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$2.3B
Intas Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Therapy Areas: | Service: | Amitone |
| Cardiovascular | Contract Manufacturing | Aspasweet |
| Diabetology | Selgin | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In August, the company and its subsidiary, Accord BioPharma, acquired the biosimilar pegfilgrastim product UDENYCA from Coherus BioSciences. |
| 2024 | Regulatory Approval | In April, Accord BioPharma secured the U.S. Food and Drug Administration approval for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab), to treat patients with HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma. |
| 2023 | New Products/Services | In June, the company launched TOFATAS, Tofacitinib Ointment 2% w/w to treat patients with mild to moderate Atopic Dermatitis (AD) in patients 18 years and above. |
Competitor Comparison
| Key Parameters | Intas Pharmaceuticals Ltd | Lupin Ltd | Torrent Pharmaceuticals Ltd | Adline Chem Lab Ltd | Allied Chemicals and Pharmaceuticals Pvt Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Ahmedabad | Mumbai | Ahmedabad | Ahmedabad | New Delhi |
| State/Province | Gujarat | Maharashtra | Gujarat | Gujarat | Delhi |
| No. of Employees | - | 19,021 | 17,320 | 4 | - |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nimish Hasmukhbhai Chudgar | Chairman; Managing Director | Executive Board | - | - |
| Binish Hasmukh Chudgar | Managing Director | Executive Board | 2016 | - |
| Udit Sakhuja | Senior General Manager-Global New Product Launch | Senior Management | 2025 | - |
| Umesh Gupta | Associate Executive Vice President - Manufacturing Operations | Senior Management | 2025 | - |
| Parthiv Mehta | Vice President - Rest of Africa & International Fertility | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer